TY - JOUR T1 - Urate, blood pressure and cardiovascular disease: updated evidence from Mendelian randomization and meta-analysis of clinical trials JF - medRxiv DO - 10.1101/2019.12.11.19014472 SP - 2019.12.11.19014472 AU - Dipender Gill AU - Alan C. Cameron AU - Stephen Burgess AU - Xue Li AU - Daniel J. Doherty AU - Ville Karhunen AU - Azmil H Abdul-Rahim AU - Martin Taylor-Rowan AU - Verena Zuber AU - Philip S. Tsao AU - Derek Klarin AU - VA Million Veteran Program AU - Evangelos Evangelou AU - Paul Elliott AU - Scott M. Damrauer AU - Terence J Quinn AU - Abbas Dehghan AU - Evropi Theodoratou AU - Jesse Dawson AU - Ioanna Tzoulaki Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/17/2019.12.11.19014472.abstract N2 - Aims To investigate the effect of serum urate on blood pressure and cardiovascular disease (CVD) risk by updating evidence from Mendelian randomization (MR) analysis and meta-analysis of randomized controlled trials (RCTs).Methods and Results Using recently available data from the Million Veterans Program and UK Biobank, the main MR analyses showed that every 1-standard deviation increase in genetically predicted serum urate was associated with an increased risk of coronary heart disease (odds ratio 1.19, 95% confidence interval 1.10-1.30, P=4×10−5), peripheral artery disease (1.12, 95%CI 1.03 to 1.21, P=9×10−3), and stroke (1.11, 95%CI 1.05 to 1.18, P=2×10−4). In MR mediation analyses, SBP was estimated to mediate approximately one third the effect of urate on CVD risk. Systematic review and meta-analysis of RCTs showed a favorable effect of urate-lowering treatment on SBP (mean difference -2.55mmHg, 95%CI -4.06 to -1.05, P=1×10−3) and major adverse cardiovascular events (MACE) in those with previous CVD (OR 0.40, 95%CI 0.22 to 0.73, P=3×10−3), but no significant effect on MACE in all individuals (OR 0.73, 95%CI 0.48 to 1.09, P=0.12).Conclusion MR and clinical trial data support an effect of higher serum urate on increasing blood pressure, which may mediate a consequent effect on CVD risk. High-quality trials are necessary to provide definitive evidence on the specific clinical contexts where urate-lowering may be of cardiovascular benefit.Competing Interest StatementDG is employed part-time by Novo Nordisk. JD and TQ have received charitable research income to conduct clinical trials of allopurinol use in people with stroke. The remaining authors have no conflicts of interest to declare.Funding StatementThis work was supported by funding from the US Department of Veterans Affairs Office of Research and Development, Million Veteran Program Grant MVP003 (I01-BX003362). This publication does not represent the views of the Department of Veterans Affairs of the US Government. DG is funded by the Wellcome 4i Clinical PhD Program at Imperial College London (203928/Z/16/Z). VK is funded by the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant (721567). PE acknowledges support from the Medical Research Council (MR/S019669/1), the National Institute for Health Research Imperial Biomedical Research Centre, Imperial College London (RDF03), the UK Dementia Research Institute (DRI) at Imperial College London funded by UK DRI Ltd (funded by Medical Research Council, Alzheimer’s Society, Alzheimer’s Research UK), and Health Data Research (HDR) UK London funded by HDR UK Ltd (funded by a consortium led by the Medical Research Council 1004231). SMD was supported by the Department of Veterans Affairs Office of Research and Development (IK2-CX001780). ET is funded by a Cancer Research UK Career Development Fellowship (C31250/A22804). The MEGASTROKE project received funding from sources specified at http://www.megastroke.org/acknowledgments.html. Details of all MEGASTROKE authors are available at http://www.megastroke.org/authors.html.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this work are either publicly accessible or available on request from their original studies, which obtained appropriate patient consent and ethical approval. The UK Biobank data were accessed through application 236. All results generated in this work are presented in either the manuscript or its supplementary files. ER -